First Trust Direct Indexing L.P. grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 19.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,257 shares of the medical instruments supplier’s stock after purchasing an additional 366 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in Becton, Dickinson and Company were worth $596,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in Becton, Dickinson and Company by 5.7% during the first quarter. BlackRock Inc. now owns 23,794,080 shares of the medical instruments supplier’s stock worth $5,889,987,000 after purchasing an additional 1,281,866 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Becton, Dickinson and Company by 1.5% in the 1st quarter. Geode Capital Management LLC now owns 5,021,220 shares of the medical instruments supplier’s stock valued at $1,239,745,000 after acquiring an additional 76,294 shares during the period. Providence Capital Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 25,185.5% in the 1st quarter. Providence Capital Advisors LLC now owns 4,492,216 shares of the medical instruments supplier’s stock valued at $18,147,000 after acquiring an additional 4,474,450 shares during the period. Moneta Group Investment Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 95,813.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 4,045,643 shares of the medical instruments supplier’s stock valued at $1,028,807,000 after acquiring an additional 4,041,425 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in shares of Becton, Dickinson and Company by 1.3% in the 4th quarter. Wells Fargo & Company MN now owns 3,801,481 shares of the medical instruments supplier’s stock valued at $966,717,000 after acquiring an additional 47,096 shares during the period. Institutional investors and hedge funds own 86.72% of the company’s stock.
Insider Buying and Selling
In related news, EVP David Hickey sold 2,974 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $277.85, for a total value of $826,325.90. Following the sale, the executive vice president now directly owns 4,199 shares in the company, valued at approximately $1,166,692.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP David Hickey sold 2,974 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $277.85, for a total value of $826,325.90. Following the completion of the transaction, the executive vice president now owns 4,199 shares of the company’s stock, valued at approximately $1,166,692.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $277.13, for a total transaction of $360,269.00. Following the completion of the transaction, the executive vice president now directly owns 5,157 shares of the company’s stock, valued at approximately $1,429,159.41. The disclosure for this sale can be found here. Insiders have sold 5,581 shares of company stock worth $1,551,429 in the last three months. Corporate insiders own 0.31% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on BDX
Becton, Dickinson and Company Price Performance
Shares of NYSE BDX opened at $265.20 on Monday. The firm has a market capitalization of $76.94 billion, a P/E ratio of 48.13, a PEG ratio of 2.20 and a beta of 0.57. Becton, Dickinson and Company has a one year low of $215.90 and a one year high of $287.32. The company’s fifty day moving average is $273.12 and its two-hundred day moving average is $258.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.73 and a current ratio of 1.25.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.96 EPS for the quarter, topping the consensus estimate of $2.89 by $0.07. Becton, Dickinson and Company had a net margin of 8.73% and a return on equity of 13.24%. The company had revenue of $4.88 billion for the quarter, compared to analyst estimates of $4.84 billion. During the same period in the previous year, the firm earned $2.66 EPS. The business’s revenue was up 5.1% on a year-over-year basis. Analysts forecast that Becton, Dickinson and Company will post 12.23 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a $0.91 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $3.64 annualized dividend and a dividend yield of 1.37%. Becton, Dickinson and Company’s dividend payout ratio is presently 66.06%.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- How to Buy Metaverse Stock Step by Step
- 3 Reasons This Sleeping Giant Is About To Wake Up
- Best Stocks Under $10.00
- MarketBeat Week in Review – 9/18 – 9/22
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 52-week Low Names To Tip The Upside Scale In Your Favor
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
